Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter, Open-Label Study To Evaluate Safety, Efficacy And Pharmacokinetics Of GFH276 In Combination With Tislelizumab, Pemetrexed And Platinum (Carboplatin Or Cisplatin) As First-Line Therapy In Participants With Locally Advanced Or Metastatic Non-Squamous Non-Small-Cell Lung Cancer Harboring RAS Mutation

NCT07846358 is registered in ClinicalTrials.gov with Genfleet Therapeutics (Shanghai) Inc. as lead sponsor.

NCT NCT07846358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07846358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter, Open-Label Study To Evaluate Safety, Efficacy And Pharmacokinetics Of GFH276 In Combination With Tislelizumab, Pemetrexed And Platinum (Carboplatin Or Cisplatin) As First-Line Therapy In Participants With Locally Advanced Or Metastatic Non-Squamous Non-Small-Cell Lung Cancer Harboring RAS Mutation
Lead sponsor
Genfleet Therapeutics (Shanghai) Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2028
Enrollment
84 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc), ras mutation